iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.
Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.
The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.
Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.
Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.
COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative fervor surrounding a potential multi-billion-dollar acquisition of the company began to dissolve, leaving investors to grapple with a "news
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.
The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.
The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence (AI)-integrated imaging software. This strategic realignment resulted in a massive $25.7 billion year-over-year jump in deal value for the diagnostics and
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year downturn that plagued the market between 2022 and 2024. This resurgence is not merely a product of
